Ameriprise
AXDX

Ameriprise’s Accelerate Diagnostics AXDX Stock Holding History

Ameriprise’s Portfolio AXDX Stock Details AXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-65
Closed -$9K – 5147
2013
Q3 		$9K Hold
65
– – ﹤0.01% 4963
2013
Q2 		$5K Buy
+65
New +$4.82K ﹤0.01% 5125

Other funds holding AXDX

OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
JMPWA
JP Morgan Private Wealth Advisors San Francisco, California $35B AUM 24.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
WIC
Wood Investment Counsel Denver, Colorado $669M AUM 20.44% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
HCS
Harvest Capital Strategies San Francisco, California $73.7M AUM 7.47% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Ameriprise's AXDX Position: Q4 2013 in Review

Ameriprise sold out of Accelerate Diagnostics (AXDX) in Q4 2013, closing a stake of 65 shares — an estimated $9K sold.

Ameriprise first reported a position in AXDX in Q2 2013 and held it in 2 quarters. The position peaked at $9K in Q3 2013. 52 funds tracked by Wall St. Rank hold AXDX as of Q4 2013.

  • Ameriprise reported no remaining Accelerate Diagnostics position as of Q4 2013 after selling out during the quarter.
  • Ameriprise sold 65 Accelerate Diagnostics shares in Q4 2013, an estimated $9K.
  • Ameriprise first reported a position in Accelerate Diagnostics in Q2 2013 and held it in 2 quarters.
  • Ameriprise's Accelerate Diagnostics position peaked at $9K in Q3 2013.
  • 52 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q4 2013.

Based on Ameriprise's 13F filing for Q4 2013, filed 14 Feb 2014.